Intercellular adhesion molecule-1 (ICAM-1) is
an adhesion molecule, member of the immunoglobulin
gene superfamily that seems to participate in the evolution
of the metastatic process. We investigated the significance
of baseline soluble ICAM-1 levels on the outcome of
patients with small-cell lung cancer and whether soluble
ICAM-1 is a predictive marker for objective response
during and after chemotherapy in patients with small-cell
lung cancer. Fifty patients with recently diagnosed smallcell
lung cancer, as well as 27 healthy smokers, were
enrolled. Blood samples were collected at the time of
diagnosis, during and at the end of chemotherapy. Data
were correlated with the characteristics of the patients and
survival as well as with ICAM-1 predictive role for
objective response. Statistical significant values of baseline
soluble ICAM between patients and controls (p\0.001)
were observed. Multivariate analysis revealed an elevated
risk of death of 9 % in the first year after diagnosis for
every 10 units of increased soluble ICAM-1 at the baseline
(p = 0.046). Performance status and disease stage were
also independent prognostic factors. Patients with extensive
disease who achieved an objective response during
chemotherapy showed a significant decrease (25.8 %) in
their soluble ICAM-1 levels compared with baseline levels
(p = 0.001). Alongside performance status and disease
stage, baseline soluble ICAM-1 could be evaluated as an
additional prognostic factor in patients with small-cell lung
cancer. Also, a possible role for soluble ICAM-1 may exist
as a predictive marker for objective response during chemotherapy
for patients with extensive disease (p = 0.001).
Άρθρα
Posted in